BH3 mimetics for the treatment of prostate cancer
Abstract: Despite improved diagnostic and therapeutic intervention, advanced prostate cancer (PC) remains incurable. The acquired resistance of PC cells to current treatment protocols has been traced to apoptosis resistance based on the upregulation of anti-apoptotic proteins of the Bcl-2 family. The use of BH3 mimetics, mimicking pro-apoptotic activator or sensitizer proteins of the intrinsic apoptotic pathway, is therefore a promising treatment strategy. The present review gives an overview of preclinical and clinical studies with pan- and specific BH3 mimetics as sensitizers for cell death and gives an outlook how they could be effectively used for the therapy of advanced PC in future
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Frontiers in pharmacology. - 8 (2017) , 00557, ISSN: 1663-9812
- DOI
-
10.3389/fphar.2017.00557
- URN
-
urn:nbn:de:bsz:25-freidok-2208129
- Rights
-
Kein Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wolf, Philipp
- Universität
Time of origin
- 2021
Other Objects (12)
BH3-mimetics: recent developments in cancer therapy
Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics
BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
Evaluation of BH3 mimetics as a novel therapeutic strategy in acute myeloid leukemia
Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells
Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells
Selective BH3 mimetics synergize with BET inhibition to induce mitochondrial apoptosis in rhabdomyosarcoma cells
BH3-mimetics: recent developments in cancer therapy
Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics
BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
Evaluation of BH3 mimetics as a novel therapeutic strategy in acute myeloid leukemia
Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells
Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells
Selective BH3 mimetics synergize with BET inhibition to induce mitochondrial apoptosis in rhabdomyosarcoma cells
BH3-mimetics: recent developments in cancer therapy
Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics
BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
Evaluation of BH3 mimetics as a novel therapeutic strategy in acute myeloid leukemia
Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells
Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells